๎๊ฒ์
๎๊ฒ์
๎
Abivax SA
ABVX๎ญ๊ด์ฌ ๋ชฉ๋ก์ ์ถ๊ฐ
114.530USD
-6.470-5.35%
์ข
๊ฐย 05/15, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
9.18B์๊ฐ์ด์ก
--P/E TTM
๎
์์ธํ ๋ด์ฉ์ Abivax SA ํ์ฌ
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ ABVX
ํ์ฌ ์ด๋ฆAbivax SA
์์ฅ์ผJun 26, 2015
CEOde Garidel (Marc)
์ง์ ์- -
์ ํDepository Receipt
ํ๊ณ ์ฐ๋ ์ข
๋ฃ- -
์ฃผ์7-11 Boulevard Haussmann
๋์PARIS
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐFrance
์ฐํธ ๋ฒํธ75009
์ ํ33153830963
์น์ฌ์ดํธhttps://www.abivax.com/
์ข
๋ชฉ ์ฝ๋ ABVX
์์ฅ์ผJun 26, 2015
CEOde Garidel (Marc)
Abivax SA์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, May 14
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, May 14
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
TCG Crossover Management, LLC
9.06%
UBS Financial Services, Inc.
5.79%
Invus Public Equities LP
5.00%
Darwin Global Management Ltd
4.05%
Point72 Asset Management, L.P.
3.07%
๊ธฐํ
73.04%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
TCG Crossover Management, LLC
9.06%
UBS Financial Services, Inc.
5.79%
Invus Public Equities LP
5.00%
Darwin Global Management Ltd
4.05%
Point72 Asset Management, L.P.
3.07%
๊ธฐํ
73.04%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Investment Advisor
30.30%
Hedge Fund
28.29%
Investment Advisor/Hedge Fund
10.60%
Research Firm
6.26%
Private Equity
1.80%
Venture Capital
1.19%
Pension Fund
0.90%
Sovereign Wealth Fund
0.06%
Bank and Trust
0.01%
๊ธฐํ
20.59%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2026Q1
353
61.40M
78.18%
-289.71K
2025Q4
216
53.64M
52.23%
+104.02K
2025Q3
210
53.54M
52.22%
+19.70M
2025Q2
81
30.74M
57.27%
-1.09M
2025Q1
75
31.82M
50.24%
-38.10K
2024Q4
68
29.91M
44.59%
+2.48M
2024Q3
54
27.43M
45.93%
-700.83K
2024Q2
51
33.52M
46.25%
-227.21K
2024Q1
46
28.78M
34.33%
+7.18M
2023Q4
33
27.04M
1.75%
+20.54M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
TCG Crossover Management, LLC
7.11M
9.67%
--
--
Dec 31, 2025
UBS Financial Services, Inc.
4.42M
6.01%
-36.99K
-0.83%
Dec 31, 2025
Invus Public Equities LP
3.92M
5.33%
+3.92M
--
Dec 31, 2025
Darwin Global Management Ltd
3.18M
4.32%
+14.00K
+0.44%
Dec 31, 2025
Point72 Asset Management, L.P.
2.41M
3.27%
-516.20K
-17.65%
Dec 31, 2025
Vestal Point Capital, LP
1.90M
2.58%
+900.00K
+90.00%
Dec 31, 2025
Morgan Stanley & Co. LLC
1.73M
2.35%
+1.10M
+172.24%
Dec 31, 2025
Caligan Partners, LP
1.45M
1.97%
--
--
Dec 31, 2025
Paradigm BioCapital Advisors LP
1.42M
1.93%
-146.72K
-9.38%
Dec 31, 2025
Fidelity Management & Research Company LLC
1.37M
1.86%
-65.02K
-4.54%
Dec 31, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
Simplify Health Care ETF
2.86%
Harbor Health Care ETF
0.7%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
๋น์จ2.86%
Harbor Health Care ETF
๋น์จ0.7%
Fidelity Nasdaq Composite Index ETF
๋น์จ0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
๋น์จ0%
Innovator IBD Breakout Opportunities ETF
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
